TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

GSK decided to abandon a TIGIT-targeted drug for cancer this week, then immediately hatched a plan to replace it with a late-stage candidate for metabolic dysfunction-associated steatohepatitis ...

iTeos to shut down following $2bn GSK-partnered TIGIT asset failure iTeos will look to distribute its cash reserves to shareholders, along with proceeds raised from selling pipeline assets.

US biotech iTeos Therapeutics (Nasdaq: ITOS) is preparing to wind down its operations and halt clinical work, as it looks to sell off assets and return value to investors following a major blow to its ...

Summary iTeos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Here, we review why the TIGIT program of Arcus and Gilead could fail in lung ...

GSK, iTeos End Anti-TIGIT Drug Development In a separate press release, the company announced that it is ending the development of the anti-TIGIT antibody belrestotug, which was being developed in ...

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a meaningful benefit in two Phase II trials.

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end development of the TIGIT-targeting antibody and halt enrollment in all ongoing ...

GSK and Massachusetts-based partner iTeos Therapeutics will no longer advance their investigational TIGIT therapy belrestotug following disappointing mid-stage results, GSK announced on Tuesday. The ...

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a meaningful benefit in two Phase II trials. Belrestotug, a human IgG1 antibody ...